ClinicalTrials.gg
Active, not recruitingNCT02351414AMETHYSTUpdated Oct 13, 2022

Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts

An observational study in Joint Disease, sponsored by MicroPort Orthopedics Inc.. Active, not recruiting at 5 sites in 5 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2022-10-13.

Sponsored by MicroPort Orthopedics Inc. (part of MicroPort Scientific Corporation) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Joint Diseases by MicroPort Scientific Corporation — 5 open to participants now, 13 under way, none of them phase 3. Joint Diseases · MicroPort Scientific Corporation.

Enrollment
2nd of 20
150 · median 69
Started
2015
with 2 others
Observational
20 of 21
5 open now
Primary completion
2027-06
later than 1 of 12 live
Registered
7th of 21
by date

Among the 21 studies in Joint Diseases by MicroPort Scientific Corporation, this one is the 2nd largest by enrollment of the 20 observational ones that give a count, is one of 3 that started in 2015, is one of 20 observational ones, reaches primary completion later than 1 of the 12 other live ones, and was the 7th registered.

Joint Diseases

386 studies on the registry are indexed under Joint Diseases; 64 are open to participants now.

Browse Joint Diseases studies →

Open to participants now

5 of the 21 studies in Joint Diseases by MicroPort Scientific Corporation are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 44 Joint Diseases studies recruiting now, 24 (55%) set no upper age limit and 11 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Joint Diseases by MicroPort Scientific Corporation, or all of them as a file.
02

Study summary

MPO is conducting this PMCF study to evaluate the safety and efficacy of its EVOLUTION® Total Knee Arthroplasty (TKA) components marketed in the EU. These types of studies are required by regulatory authorities for all devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the EU. This study has been designed in accordance with MEDDEV 2.12/2 rev 2.

Read the detailed description

MicroPort Orthopedics Inc. (MPO) currently markets the EVOLUTION® TKA System globally, including in the European Union (EU). As part of the process for gaining approval to market in the EU, MicroPort is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of this system. These types of studies are required by regulatory authorities for all TKA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the EU. The objectives of this study are to evaluate component survivorship, cumulative revision rate, functional outcome scores, and subject satisfaction at early, midterm, and long-term follow-up.

03

Conditions studied

  • Joint Disease

Keywords

  • Osteoarthritis
  • Ankylosis
  • Revision procedures
  • Correction of functional deformity
  • Rheumatoid arthritis
  • Arthritis
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who have been previously implanted with the EVOLUTION® TKA System with cruciate sacrificing (CS) inserts

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be included in the study, subjects must meet all of the following criteria:

  • Has previously undergone primary TKA for any of the following:
  • non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis;
  • inflammatory degenerative joint disease including rheumatoid arthritis
  • correction of functional deformity.
  • Subject was implanted with the specified combination of components
  • Subject is willing and able to complete required study visits and assessments
  • Subject plans to be available through the 10 year postoperative follow-up visit
  • Subject is willing to sign the approved document
  • Subject must be at least 2 years post TKA prior to informed consent.

Previously implanted bilateral subjects can have both TKAs enrolled in the study provided: 1) the specified combination of components were implanted in both, 2) all other aspects of the Inclusion/Exclusion Criteria are satisfied, 3) enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and 4) the subject agrees to a second Informed Consent document specific to the second TKA. Prospective enrollment of a previously unimplanted knee is not permitted in this study.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded if they meet any of the following criteria:

  • Subject was skeletally immature (less than 21 years of age) at time of implantation
  • Subject is currently enrolled in another clinical investigation
  • Subject is unwilling or unable to sign the document
  • Subject has documented substance abuse issues
  • Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study
  • Subject has a (BMI) of greater than 40
  • Subject is currently incarcerated or has impending incarceration
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (actual)
Patient registry
No

Groups and cohorts

  • Primary Total Knee Arthroplasty

    Single study group previously implanted with the EVOLUTION® TKA System with cruciate sacrificing (CS) inserts

    Device: Total Knee Arthroplasty (EVOLUTION®)

Interventions

  • DeviceTotal Knee Arthroplasty (EVOLUTION®)

    Also known as: EVOLUTION® Total Knee Arthroplasty System with CS Inserts, EVOLUTION® CS

06

What researchers measure

Primary outcomes

  1. Component Survivorship

    The primary endpoints are analysis of survivorship for all components at each follow-up interval out to 10 years

    Time frame: 10 years post-operative

Secondary outcomes

  1. Patient functional outcomes scores (assessed by KOOS Scores and EQ-5D-3L Scores)

    To characterize functional scores for subjects, as assessed by KOOS Scores and EQ-5D-3L Scores

    Time frame: 2-<5 years, 5-7 years, and 10 years

  2. Cumulative Revision Rate

    To determine the cumulative revision rate at specified intervals out to 10 years follow-up

    Time frame: 2-<5 years, 5-7 years, and 10 years

  3. Subject Satisfaction (assessed by Patient Satisfaction Questionnaires)

    To assess subject satisfaction with their TKA procedure

    Time frame: 2-<5 years, 5-7 years, and 10 years

  4. Number of Radiolucencies

    To summarize the number of radiolucencies in zones surrounding implanted components

    Time frame: 2-<5 years, 5-7 years, and 10 years

  5. Size of Radiolucencies

    To summarize the size of radiolucencies in zones surrounding implanted components

    Time frame: 2-<5 years, 5-7 years, and 10 years

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2015 (actual). Primary completion is estimated for Jun 2027, 144 months after the start.

Of 58 observational studies under Joint Diseases, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 153. This study's planned 144 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2015
First posted
Jan 30, 2015
StartActual
Jun 15, 2015
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2028
Last update
Oct 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02351414
Responsible party
Sponsor
First posted
Jan 30, 2015
Start date
Jun 15, 2015
Primary completion
Jun 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 13, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion